(NASDAQ: NRIX) Nurix Therapeutics's forecast annual revenue growth rate of 57.65% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.5%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 9.23%.
Nurix Therapeutics's revenue in 2023 is $39,240,000.On average, 4 Wall Street analysts forecast NRIX's revenue for 2023 to be $3,392,990,060, with the lowest NRIX revenue forecast at $1,296,563,978, and the highest NRIX revenue forecast at $5,530,906,189. On average, 3 Wall Street analysts forecast NRIX's revenue for 2024 to be $5,321,004,268, with the lowest NRIX revenue forecast at $2,545,980,174, and the highest NRIX revenue forecast at $8,569,109,197.
In 2025, NRIX is forecast to generate $4,153,719,506 in revenue, with the lowest revenue forecast at $3,536,083,575 and the highest revenue forecast at $4,771,355,437.